BIOPATCH 3151
Report
- Report Number
- 2648988-2010-00019
- Event Type
- Other
- Date Received
- March 19, 2010
- Date of Event
- April 4, 2008
- Report Date
- March 19, 2010
- Manufacturer
- INTEGRA NEUROSCIENCES PR
- Product Code
- FRO
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NJ, US
- Reporter Occupation
- OTHER
Narratives
A RECENT INTERNAL AUDIT OF INVESTIGATED COMPLAINTS THAT HAVE BEEN RECEIVED DURING THE PAST TWO YRS DETERMINED THAT THIS EVENT, THAT FULFILLS INTEGRA LIFESCIENCES CORP'S REPORTING REQUIREMENTS, WAS NOT REPORTED PREVIOUSLY TO THE FDA. NO LOT NUMBER WAS PROVIDED AND NO PRODUCT COMPLAINT SAMPLE WAS AVAILABLE FOR RETURN FOR EXAMINATION. AS A RESULT, THE DEVICE HISTORY RECORD COULD NOT BE REVIEWED. INTEGRA'S INVESTIGATION WAS UNABLE TO CONFIRM THE COMPLAINT. NO CORRECTIVE ACTION IS CONSIDERED TO BE NECESSARY. THE COMPLAINT RATE FOR THIS PRODUCT FAMILY IS 0.0005%. INTEGRA CONSIDERS THIS COMPLAINT INVESTIGATION CLOSED. FUTURE INCIDENTS OF THIS NATURE WILL BE DOCUMENTED FOR RECURRENCE AND TRENDING PURPOSES.
THE REPORTER STATED THAT A BIOPATCH WAS USED AS A DRESSING ON THE INSERTION SITE OF A SUBCLAVIAN TRIPLE LUMEN CATHETER THAT WAS IN PLACE TO ADMINISTER NORMAL SALINE AND INTRAVENOUS MEDICATION. THE CATHETER WAS IN PLACE FOR FIVE DAYS. WHEN THE BIOPATCH DRESSING WAS CHANGED AFTER FIVE DAYS, THERE WAS NO ABNORMALITY NOTED. AFTER A FURTHER FIVE DAYS, PUS AND REDNESS WERE OBSERVED AT THE CATHETER INSERTION SITE. ON REMOVAL OF THE CATHETER, THE CATHETER TIP WAS SENT FOR BACTERIAL CULTURE. THE RESULTS OF THE CULTURE WERE NEGATIVE. A NEW SUBCLAVIAN LINE WAS INSERTED AT A SITE ON THE PT'S OPPOSITE SIDE. NO FURTHER TREATMENT WAS PROVIDED. BIOPATCH WAS USED AGAIN ON THIS PT WITHOUT FURTHER INCIDENT.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | BIOPATCH 3151 | ANTIMICROBIAL PRODUCTS | FRO | INTEGRA NEUROSCIENCES PR |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Other |